ClinicalTrials.gg
CompletedNCT01745055Updated Feb 4, 2013Results posted

Co-Administration Of Methotrexate And CP-690,550

A Phase 1 interventional study of CP-690,550 (tofacitinib) and Methotrexate (MTX) in Rheumatoid Arthritis, sponsored by Pfizer. Completed at 4 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2013-02-04.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 43 studies testing tofacitinib in Arthritis, Rheumatoid — 9 open to participants now, 9 under way, 1 of them phase 3. tofacitinib · Arthritis, Rheumatoid.

Enrollment
39th of 43
12 · median 170
Started
2005
with 1 other
Phase 1
6 of 43
none open now
Registered
20th of 43
by date
Lead sponsor
25 of 43
Pfizer

Among the 43 studies testing tofacitinib in Arthritis, Rheumatoid, this one is the 39th largest by enrollment, is one of 2 that started in 2005, is one of 6 in phase 1, and was the 20th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

9 of the 43 studies testing tofacitinib in Arthritis, Rheumatoid are open now, in 6 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About tofacitinib

tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tofacitinib in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This study was designed to estimate the effects of methotrexate (MTX) on the pharmacokinetics (PK) of CP-690,550 when administered to subjects with rheumatoid arthritis (RA), to estimate the effects of CP-690,550 on the PK of MTX and to evaluate the short-term safety and tolerability of co-administration of CP-690,550 and MTX.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Pharmacokinetics
  • oral JAK inhibitor
  • methotrexate (MTX)
  • rheumatoid arthritis (RA)
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults diagnosed with moderate to severe RA (Rheumatoid Arthritis)
  • Diagnosis of RA based on the American College of Rheumatology 1987 revised criteria.
  • Treatment with an oral stable weekly dose of Methotrexate (MTX) (15-25 mg/week, administered as a single dose [SD]) for a minimum of 4 doses (4 weeks)

Exclusion criteria

Exclusion Criteria:

  • Blood dyscrasias including confirmed: \<9 g/dL or Hematocrit \<30%; White blood cell count \<3.0 x 109/L; \<1.2 x 109/L; count \<100 x 109/L
  • Evidence or history of infections within the past 6 months (eg, those requiring hospitalization, requiring parenteral antimicrobial therapy, or those with recurrent oral or genital herpes, recurrent herpes zoster, or any infection otherwise judged by the investigator to have the potential for exacerbation by participation in the trial.
  • Total , (aspartate aminotransferase) or ALT (alanine aminotransferase) more than 1.2 times the at the Screening visit, or a history of clinically significant elevated liver function tests (LFTs) while on current MTX dose or chronic liver disease, recent or active hepatitis.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    CP-690,550 (tofacitinib) 30 mg q12h

    Individual dose of methotrexate with the addition of CP-690,550 30 mg q12h

    Drug: CP-690,550 (tofacitinib) · Drug: Methotrexate (MTX)

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Curve From Time Zero to 12 Hours [AUC (0-12)] for CP-690,550

    AUC (0-12)= area under the plasma concentration time-curve from time zero (pre-dose) to 12 hours (0-12).

    Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8 and 12 hours post-dose on Day 6 and Day 7

  2. Maximum Observed Plasma Concentration (Cmax) for CP-690,550

    Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8 and 12 hours post-dose on Day 6 and Day 7

  3. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Methotrexate (MTX)

    Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).

    Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 and 48 hours post-dose on Day 1 and Day 7

  4. Maximum Observed Plasma Concentration (Cmax) for Methotrexate (MTX)

    Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8,12, 24 and 48 hours post-dose on Day 1 and Day 7

Secondary outcomes

  1. Time to Reach Maximum Observed Plasma Concentration (Tmax) for CP-690,550

    Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8 and 12 hours post-dose on Day 6 and Day 7

  2. Plasma Decay Half-Life (t1/2) for CP-690,550

    Plasma decay half-life is the time measured for the plasma concentration of CP-690,550 to decrease by one half.

    Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8 and 12 hours post-dose on Day 6 and Day 7

  3. Apparent Oral Clearance (CL/F) for CP-690,550

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population PK modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8 and 12 hours post-dose on Day 6 and Day 7

  4. Time to Reach Maximum Observed Plasma Concentration (Tmax) for Methotrexate (MTX)

    Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8 ,12, 24 and 48 hours post-dose on Day 1 and Day 7

  5. Plasma Decay Half-Life (t1/2) for Methotrexate (MTX)

    Plasma decay half-life is the time measured for the plasma concentration of MTX to decrease by one half.

    Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8 , 12, 24 and 48 hours post-dose on Day 1 and Day 7

  6. Apparent Oral Clearance (CL/F) for Methotrexate (MTX)

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population PK modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8 , 12, 24 and 48 hours post-dose on Day 1 and Day 7

  7. Total Amount of Unchanged Drug Excreted in the Urine From Time Zero to 12 Hours (Ae[0-12]) for CP-690,550

    Time frame: 0 (pre-dose) through 12 hours post-dose on Day 6 and Day 7

  8. Renal Clearance (CL R) for CP-690,550

    Time frame: 0 (pre-dose) through 24 hours post-dose on Day 6 and Day 7

  9. Total Amount of Unchanged Drug Excreted in the Urine From Time Zero to 24 Hours (Ae[0-24]) for Methotrexate (MTX)

    Time frame: 0 (pre-dose) through 24 hours post-dose on Day 1 and Day 7

  10. Renal Clearance (CL R) for Methotrexate (MTX)

    Time frame: 0 (pre-dose) through 24 hours post-dose on Day 1 and Day 7

07

Results

Posted Dec 7, 2012
Limitations and caveats
Results were summarized for Ae(0-12) instead of planned Ae(0-24), as CP-690,550 was administered every 12 hours.

Participant flow

Participant flow — Overall Study
MilestoneMethotrexate + CP-690,550
Started12
Completed12
Not completed0

Outcome measures

PrimaryArea Under the Curve From Time Zero to 12 Hours [AUC (0-12)] for CP-690,550

AUC (0-12)= area under the plasma concentration time-curve from time zero (pre-dose) to 12 hours (0-12).

Time frame:
0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8 and 12 hours post-dose on Day 6 and Day 7
Reported as:
Mean · nanogram*hour/milliliter (ng*hr/mL)
Area Under the Curve From Time Zero to 12 Hours [AUC (0-12)] for CP-690,550
nanogram*hour/milliliter (ng*hr/mL)CP-690,500Methotrexate + CP-690,500
Area Under the Curve From Time Zero to 12 Hours [AUC (0-12)] for CP-690,5501370 ± 4231410 ± 425
Statistical analysis
  • CP-690,500 vs Methotrexate + CP-690,500 · Ratio of adjusted geometric means: 103.06 · 90% CI 99.00 to 107.29
PrimaryMaximum Observed Plasma Concentration (Cmax) for CP-690,550
Time frame:
0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8 and 12 hours post-dose on Day 6 and Day 7
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) for CP-690,550
ng/mLCP-690,500Methotrexate + CP-690,500
Maximum Observed Plasma Concentration (Cmax) for CP-690,550375 ± 91.6384 ± 84.8
Statistical analysis
  • CP-690,500 vs Methotrexate + CP-690,500 · Ratio of adjusted geometric means: 102.71 · 90% CI 93.79 to 112.47
PrimaryArea Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Methotrexate (MTX)

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).

Time frame:
0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 and 48 hours post-dose on Day 1 and Day 7
Reported as:
Mean · ng*hr/mL
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Methotrexate (MTX)
ng*hr/mLMethotrexateMethotrexate + CP-690,500
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Methotrexate (MTX)1850 ± 6851720 ± 753
Statistical analysis
  • Methotrexate vs Methotrexate + CP-690,500 · Ratio of adjusted geometric means: 89.53 · 90% CI 77.38 to 103.57
PrimaryMaximum Observed Plasma Concentration (Cmax) for Methotrexate (MTX)
Time frame:
0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8,12, 24 and 48 hours post-dose on Day 1 and Day 7
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) for Methotrexate (MTX)
ng/mLMethotrexateMethotrexate + CP-690,500
Maximum Observed Plasma Concentration (Cmax) for Methotrexate (MTX)478 ± 106433 ± 175
Statistical analysis
  • Methotrexate vs Methotrexate + CP-690,500 · Ratio of adjusted geometric means: 87.25 · 90% CI 76.03 to 100.12
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) for CP-690,550
Time frame:
0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8 and 12 hours post-dose on Day 6 and Day 7
Reported as:
Median · hour
Time to Reach Maximum Observed Plasma Concentration (Tmax) for CP-690,550
hourCP-690,500Methotrexate + CP-690,500
Time to Reach Maximum Observed Plasma Concentration (Tmax) for CP-690,5501.00 (0.50 to 1.00)1.00 (0.50 to 1.00)
SecondaryPlasma Decay Half-Life (t1/2) for CP-690,550

Plasma decay half-life is the time measured for the plasma concentration of CP-690,550 to decrease by one half.

Time frame:
0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8 and 12 hours post-dose on Day 6 and Day 7
Reported as:
Mean · hour
Plasma Decay Half-Life (t1/2) for CP-690,550
hourCP-690,500Methotrexate + CP-690,500
Plasma Decay Half-Life (t1/2) for CP-690,5502.64 ± 0.3563.12 ± 0.74
SecondaryApparent Oral Clearance (CL/F) for CP-690,550

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population PK modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

Time frame:
0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8 and 12 hours post-dose on Day 6 and Day 7
Reported as:
Mean · mL/hr
Apparent Oral Clearance (CL/F) for CP-690,550
mL/hrCP-690,500Methotrexate + CP-690,500
Apparent Oral Clearance (CL/F) for CP-690,55023200 ± 838023511 ± 8784
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) for Methotrexate (MTX)
Time frame:
0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8 ,12, 24 and 48 hours post-dose on Day 1 and Day 7
Reported as:
Median · hour
Time to Reach Maximum Observed Plasma Concentration (Tmax) for Methotrexate (MTX)
hourMethotrexateMethotrexate + CP-690,500
Time to Reach Maximum Observed Plasma Concentration (Tmax) for Methotrexate (MTX)1.00 (0.50 to 1.50)1.25 (0.50 to 2.00)
SecondaryPlasma Decay Half-Life (t1/2) for Methotrexate (MTX)

Plasma decay half-life is the time measured for the plasma concentration of MTX to decrease by one half.

Time frame:
0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8 , 12, 24 and 48 hours post-dose on Day 1 and Day 7
Reported as:
Mean · hour
Plasma Decay Half-Life (t1/2) for Methotrexate (MTX)
hourMethotrexateMethotrexate + CP-690,500
Plasma Decay Half-Life (t1/2) for Methotrexate (MTX)2.87 ± 0.9623.36 ± 1.13
SecondaryApparent Oral Clearance (CL/F) for Methotrexate (MTX)

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population PK modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

Time frame:
0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8 , 12, 24 and 48 hours post-dose on Day 1 and Day 7
Reported as:
Mean · mL/hr
Apparent Oral Clearance (CL/F) for Methotrexate (MTX)
mL/hrMethotrexateMethotrexate + CP-690,500
Apparent Oral Clearance (CL/F) for Methotrexate (MTX)9890 ± 337011500 ± 5430
SecondaryTotal Amount of Unchanged Drug Excreted in the Urine From Time Zero to 12 Hours (Ae[0-12]) for CP-690,550
Time frame:
0 (pre-dose) through 12 hours post-dose on Day 6 and Day 7
Reported as:
Mean · milligram
Total Amount of Unchanged Drug Excreted in the Urine From Time Zero to 12 Hours (Ae[0-12]) for CP-690,550
milligramCP-690,500Methotrexate + CP-690,500
Total Amount of Unchanged Drug Excreted in the Urine From Time Zero to 12 Hours (Ae[0-12]) for CP-690,5506.65 ± 2.266.58 ± 2.34
SecondaryRenal Clearance (CL R) for CP-690,550
Time frame:
0 (pre-dose) through 24 hours post-dose on Day 6 and Day 7
Reported as:
Mean · litre/hour (L/hr)
Renal Clearance (CL R) for CP-690,550
litre/hour (L/hr)CP-690,500Methotrexate + CP-690,500
Renal Clearance (CL R) for CP-690,5505490 ± 28905240 ± 2630
SecondaryTotal Amount of Unchanged Drug Excreted in the Urine From Time Zero to 24 Hours (Ae[0-24]) for Methotrexate (MTX)
Time frame:
0 (pre-dose) through 24 hours post-dose on Day 1 and Day 7
Reported as:
Mean · milligram
Total Amount of Unchanged Drug Excreted in the Urine From Time Zero to 24 Hours (Ae[0-24]) for Methotrexate (MTX)
milligramMethotrexateMethotrexate + CP-690,500
Total Amount of Unchanged Drug Excreted in the Urine From Time Zero to 24 Hours (Ae[0-24]) for Methotrexate (MTX)18.1 ± 9.3113.2 ± 4.38
SecondaryRenal Clearance (CL R) for Methotrexate (MTX)
Time frame:
0 (pre-dose) through 24 hours post-dose on Day 1 and Day 7
Reported as:
Mean · L/hr
Renal Clearance (CL R) for Methotrexate (MTX)
L/hrMethotrexateMethotrexate + CP-690,500
Renal Clearance (CL R) for Methotrexate (MTX)10.2 ± 4.568.95 ± 4.64

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Methotrexate—0/12 (0%)5/12 (41.7%)
CP-690,500—0/12 (0%)6/12 (50%)
Methotrexate + CP-690,500—0/12 (0%)5/12 (41.7%)
Most frequent other events
Showing 10 of 18
Most frequent other events
EventMethotrexateCP-690,500Methotrexate + CP-690,500
AnemiaBlood and lymphatic system disorders0/120/122/12
NauseaGastrointestinal disorders0/122/121/12
HeadacheNervous system disorders2/121/120/12
SinusitisInfections and infestations1/121/121/12
ArthralgiaMusculoskeletal and connective tissue disorders1/121/121/12
Back painMusculoskeletal and connective tissue disorders1/121/121/12
Muscle fatigueMusculoskeletal and connective tissue disorders0/121/120/12
Musculoskeletal chest painMusculoskeletal and connective tissue disorders1/121/121/12
Musculoskeletal stiffnessMusculoskeletal and connective tissue disorders1/120/120/12
Pain in extremityMusculoskeletal and connective tissue disorders0/121/121/12

Baseline characteristics

Age Continuous
Age Continuous(years)Methotrexate + CP-690,550
Mean57.3 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)Methotrexate + CP-690,550
Female8
Male4
08

Study locations

4 sites
  • Pfizer Investigational Site
    Daytona Beach, Florida 32114, United States
  • Pfizer Investigational Site
    Fort Lauderdale, Florida 33301, United States
  • Pfizer Investigational Site
    Miramar, Florida 33025, United States
  • Pfizer Investigational Site
    Dallas, Texas 75247, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2005, a primary completion of Jun 2006 and a completion of Jun 2006. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2012, 6 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2012
First posted
Dec 7, 2012
Start
Apr 2005
Primary completionActual
Jun 2006
CompletionActual
Jun 2006
Results first posted
Dec 7, 2012
Last update
Feb 4, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01745055
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Dec 7, 2012
Start date
Apr 2005
Primary completion
Jun 2006
Completion
Jun 2006
Results posted
Dec 7, 2012
Last update
Feb 4, 2013

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofacitinib

Start the discussion